Abstract
BackgroundRegulation has not kept pace with the growth of the hemp-derived CBD market. We have evaluated the risk of Δ9-tetrahydrocannabinol (Δ9-THC) contamination in 80 unregulated products with comparison to a regulated control, Epidiolex®. MethodsLocal and national brands of hemp-derived oil products were purchased online and from local retailers in central Kentucky (which carry both national and local brands). These were extracted by solvent extraction and quantified by liquid-chromatography tandem mass-spectrometry (LC-MS/MS) using a validated method. ResultsOf the 80 unregulated products and Epidiolex®, Δ9-THC was detected above the limit of quantification (LOQ = 0.005 mg/mL) of the assay in 52 samples, ranging from 0.008 mg/mL to 2.071 mg/mL. Twenty-one of the products tested were labelled as “THC-Free”, and 5 of these products contained detectable levels of Δ9-THC ranging from 0.015 mg/mL to 0.656 mg/mL. ConclusionsConsumers are taking hemp-derived CBD products without understanding the risks of unintentional consumption of Δ9-THC. This accidental use of Δ9-THC could have adverse effects on health and safety as well as potential legal consequences (e.g., child custody, impaired driving), as Δ9-THC drug test findings could impact employment, military, and sport eligibility status.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
